ArticleFrontiers in medicine2025
En face swept-source optical coherence tomography (SS-OCT) and SS-OCT angiography findings of retinal astrocytic hamartomas in patients with tuberous sclerosis complex.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by multisystem hamartomas, including retinal astrocytic hamartomas (RAHs), which are a key diagnostic criterion. This study evaluates the en face swept-source optical coherence tomography (SS-OCT) and SS-OCT angiography (SS-OCTA) features of TSC-associated RAHs. Methods: A retrospective analysis of 10 patients with TSC-associated RAHs was conducted using en face SS-OCT, SS-OCTA, and fundus photography. Structural and vascular features of the lesions were assessed based on these imaging modalities. Results: Of the 10 TSC patients, 21 RAH lesions (18 type 1, 1 type 2, 2 type 3) were completely scanned. En face SS-OCT revealed vitreous changes in 17 of the 21 RAH lesions, with clear visualization of vitreoretinal traction in 6 lesions. Type 1 RAHs appeared as isoreflective or mildly hyporeflective masses with disarrangement of retinal nerve fibers. Calcified components in type 2 or type 3 RAHs appeared differently on the en face choroid slab, with type 2 RAHs featuring closely arranged isoreflective vesicles, while type 3 RAHs appeared as sharply defined dark areas. On SS-OCTA, a dense vascular network with disorganization of the radial papillary capillaries was observed in almost all of the type 1 RAHs, with half of them exhibiting congestive intrinsic microvasculature. Feeder vessels were identified in only two type 1 lesions. Non-flow, moth-eaten cavities were characteristic of the calcified components of type 2 or type 3 RAHs. The tumor vascular density was positively correlated with tumor maximal thickness in type 1 RAHs ( Conclusion: En face SS-OCT provided a good display of RAH-related vitreoretinal traction and tumor calcification, while SS-OCTA, by clearly visualizing intratumoral vascularity, may assist in detecting signs of progressive tumor growth in TSC-associated RAHs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.